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TherapyAutosomal Recessive Osteopetrosis is a genetic disorder characterized by increased bone density due to lack of
resorption by the osteoclasts. Genetic studies have widely unraveled the molecular basis of the most severe
forms, while cases of intermediate severity are more difﬁcult to characterize, probably because of a large hetero-
geneity. Here, we describe the use of exome sequencing in the molecular diagnosis of 2 siblings initially thought
to be affected by “intermediate osteopetrosis”, which identiﬁed a homozygous mutation in the CTSK gene.
Prompted by this ﬁnding, we tested by Sanger sequencing 25 additional patients addressed to us for recessive
osteopetrosis and found CTSK mutations in 4 of them. In retrospect, their clinical and radiographic features
were found to be compatible with, but not typical for, Pycnodysostosis. We sought to identify modiﬁer genes
that might have played a role in the clinical manifestation of the disease in these patients, but our results were
not informative. In conclusion, we underline the difﬁculties of differential diagnosis in some patients whose
clinical appearance does not ﬁt the classical malignant or benign picture and recommend that CTSK gene be
included in the molecular diagnosis of high bone density conditions.
© 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
The osteopetroses are a group of clinically and genetically heteroge-
neous bone diseases sharing the hallmark of increased bone density on
radiographs [1]. This pathological feature results from abnormalities in
either osteoclast differentiation or function [2]. Clinical and molecular
dissection of osteopetroses has identiﬁed forms with different severity
and prognosis [3], even though classiﬁcation of single patients into a
speciﬁc subgroup is not always easy due to the rareness of these condi-
tions and to the presence of a variety of additional clinical features. On
the other hand, the possibility to obtain a precise molecular diagnosis
importantly impacts on the patients' management [2,3].earch Center, Via Manzoni 113,
it (C. Sobacchi).
c. Open access under CC BY-NC-ND licSince its ﬁrst application few years ago [4–6], whole exome
sequencing has been exploited to identify the causative gene of many
monogenic disorders, including skeletal diseases. Exome sequencing
offers the great advantage that large groups of affected individuals are
not required; on the contrary, the analysis can be successfully conducted
in a single family, which is very useful when only atypical or extremely
rare forms of a heterogeneous disease are left for diagnosis.
Herewe report the results of exome sequencing in 2 siblingswith an
initial clinical diagnosis of intermediate osteopetrosis, which identiﬁed
a mutation in the Cathepsin K (CTSK) gene, known to cause Pycno-
dysostosis (MIM 265800). This ﬁnding prompted us to analyze the
same gene in 25 patients addressed to us with a clinical diagnosis of
recessive osteopetrosis with no recognized genotype, leading to the
identiﬁcation of mutations in CTSK in 4 additional patients.
The cathepsins constitute a family of lysosomal cysteine proteases
responsible for several important cellular processes [7]. They are pro-
duced in an inactive form containing an N-terminal proregion, which
is cleaved upon activation and required for proper protein folding and
intracellular trafﬁcking, and for inhibition of the proteolytic function
until the proenzyme reaches the lysosome [8]. In particular, Cathepsinense.
123A. Pangrazio et al. / Bone 59 (2014) 122–126K is a marker of late osteoclast differentiation with an important role in
the degradation of bone organic matrix [9]. In addition, studies in
animal models demonstrated its involvement in autoimmune and
inﬂammatory diseases through regulation of Toll-like receptor 9 (TLR9)
signaling [10].
Our molecular results allowed redirecting the clinical diagnosis in
6 patients, in support of the possibility that exome sequencing is
routinely used as a diagnostic tool in the near future, especially for dis-
orders that share a common clinical presentation but are genetically
heterogeneous.Materials and methods
Samples
Clinical data and specimens, including blood and DNA samples,
were collected from patients and their parents after informed consent.
This research complies with the standards established by the
Independent Ethical Committee of the Humanitas Clinical and Research
Centre.Exome analysis
Exome capture was performed using 1.5 μg of high-quality genomic
DNA from each patient and the TruSeq Exome Enrichment Kit
(Illumina) that provides coverage across 62 Mb of exomic sequence,
including 5′ UTR, 3′ UTR, microRNA and other non-coding regions. The
enriched library was validated by the Agilent DNA 1000 Kit and loaded
on the cBot Station (Illumina) to create clonal clusters on the ﬂow
cell. Sequencing was performed at the CRS4 center (Centro di
Ricerca, Sviluppo e Studi Superiori in Sardegna, Italy) on the Hiseq2000
Instrument. Reads extracted with the Illumina tools were aligned to
the reference genome hg19 by using Seal 0.2.3 and stored in compressed
binary ﬁles (BAM). Single nucleotide variations as well as insertions and
deletions were called using the Genome Analysis Toolkit (GATK) [11].
Quality controls were performed using the QC Tool [12]. The variants
thus identiﬁed were merged in a unique list, in a Variant Call Format
(VCF) ﬁle, and successively annotated by ANNOtation of genetic
VARiants (ANNOVAR) [13]. Finally, variants were further prioritized
and ﬁltered according to a basic workﬂow for exome sequencing.Sanger sequencing
CTSK gene ampliﬁcation and direct sequencing of exons and intron–
exon boundaries were performed as described [14]. The mutation
nomenclature conforms to HGVS (www.hgvs.org/mutnomen) [15];
the reference sequence for the genomic DNA is GenBank NC_000001.
10, while for the cDNA is GenBank NM_000396.2 (the numbering
starts with nucleotide +1 for the A of the ATG-translation initiation
codon).
Primer sequences and conditions for ampliﬁcation and sequencing
of selected genomic regions of Low density lipoprotein receptor-
related protein 4 (LRP4), Filamin B (FLNB), Cerberus 1 homolog (CER1)
and Osteopontin (OPTN) genes are available upon request.In silico analysis
The putative effect of the mutations identiﬁed in CTSK gene was
predicted using the publicly available tools Mutation Taster (http://
www.mutationtaster.org/), PolyPhen-2 (http://genetics.bwh.harvard.
edu/pph2/), SIFT and Provean (http://provean.jcvi.org/genome_submit.
php).Results
Patients
Family 1 came from Kashmir (Pakistan) and comprised 2 affected
siblings born from consanguineous parents (ﬁrst cousins). Both patients
were reported to have a “slow onset” form of osteopetrosis which was
thought to be of autosomal recessive inheritance due to parental con-
sanguinity and the absence of symptoms possibly related to the disease
in their parents. The elder child (Patient 1A) had a transient anemia as
an infant, but since has had normal blood counts (Hb 12 g/dl, WBC
10.1 × 109/l, neutrophils 2.37 × 109/l and platelets 255 × 109/l, at
12 years). Growth retardation was reported and became more striking
with the age (height b0.4th centile and weight at 0.4th centile) at
12 years. She presented with proptosis and became totally blind when
she was 5 years old. At 11 years she had an episode of dysesthesia in
both arms and legs and anMRI examination showed a Chiarimalforma-
tion. An intra-ventricular shunt was inserted to reduce intracranial
pressure. At the moment she is not receiving any therapy, attending
school in reasonably good conditions.
Her younger sister (Patient 1B) was diagnosed in the ﬁrst year of
life due to family history, and showed mild anemia and short stature
(height b3rd centile at 34 months). Diagnosis was conﬁrmed by
plain X-rays. When she was 2.5 years old, she began to display visual
impairment, despite normal visual evoked potentials (VEP). Bronchiec-
tasis was also present. At 3 years she received matched bone marrow
transplantation (BMT) after conditioning according to the European
Group for BoneMarrowTransplantation-European Society for Immuno-
deﬁciencies (EBMT-ESID) guidelines (www.esid.org/downloads/
OPGuidelines-2011). She reached full engraftment, even though bone
improvementwas evident only after 5 months; post-transplant compli-
cations were graft versus host disease (GvHD), grade 1, and transient
mild veno-occlusive disease (VOD). Ophthalmological follow-up
showed slightly reduced visual acuity (right−0.14 and left 0.14), full
visual ﬁelds and pink optic nerves. Growth is poor at 8.5 years even
though partially improved post-BMT (height from 0.3 cm below the
0.4th centile before BMT to 0.1 cm below the 0.4th centile). Hematolog-
ical parameters are now within normal range.
Patient 2 was born from consanguineous Pakistani parents (ﬁrst
cousins). She presented with the complaint of progressive pallor for
one month at 12 years of age. On examination she showed severe
anemia (Hb 6.3 g/dl) and splenomegaly, raising the suspicion of hemo-
lytic anemia; however, work up turned out to be negative. The presence
of growth retardation (height b2nd centile, weight 9th centile) and
complete skeletal survey led to the diagnosis of osteopetrosis (see
Fig. 1a upper panel, for the most recent radiological cranial evaluation).
She was initially treated with steroids and calcitriol and then received
blood transfusion from the age of 15; at present (17 years old) she is
on calcitriol only. She presents proptosis, malar prominence and short
stature.
Patient 3 was born from consanguineous Bangladeshi parents. He
was diagnosed with mild osteopetrosis at 9 months due to a general-
ized increase in bone density on X-ray and visual impairment requiring
optic nerve decompression (at 9 years of age), while the hematological
compartment was normal. He has had also recurrent mal-uniting frac-
tures of the femur. At present he is alive and clinically stable at
19 years of age.
Patient 4 was born from Black Caribbean unrelated parents. She was
accidentally diagnosed at 3 years of age, during a routine X-ray per-
formed after swallowing a screw. She also displayed moderate anemia
(Hb 10.4 g/dl) and mild visual impairment with a slight nystagmus,
while on a CT scan foramenmagnumnarrowing and a syrinxwere pres-
ent. At the age of 7 she underwent a foramen magnum decompression
for cerebellar tonsil ectopia and developed hydrocephalus in the post-
operative period requiring placement of ventriculo-peritoneal shunt.
She is alive at 10 years of age with stable hematological conditions, an
Fig. 1. Selected radiographs of Patient 2 at 17 years of age, Patient 4 at 8 years of age and Patient 5 at 4 years of age. A diffuse increased bone density is evident. Panel a: Lateral view of the
skull (Patient 2 top; Patient 4middle; Patient 5 bottom). Loss of themandible angle is present only in Patient 5, which also presents wormian bones. The superposition on the X-ray in the
middle is caused by braids (the patient being of Caribbean origin). Panel b: Hand radiographs of Patient 4 (left) and Patient 5 (right). The distal phalangeal tufts are small and thismight be
considered an early sign of acroosteolysis (but also a normal variant); however no overt signs of acroosteolysis are present, possibly because of their relatively young age. Only the
diaphyseal constriction of metacarpals in Patient 5 is suggestive of Pycnodysostosis. Panel c: “Sandwich vertebrae” in Patient 5. The lateral view shows peripheral bone sclerosis with
central hypo-densities and a wide anterior notch corresponding to the arterial canal.
124 A. Pangrazio et al. / Bone 59 (2014) 122–126important syrinx in the spinal cord, and obstructive sleep apnea requir-
ing nocturnal continuous positive airway pressure. The available X-rays
also show scaphocephaly (Fig. 1a central panel), which is rarely seen
in osteopetrosis while it has been reported in Pycnodysostosis; distal
phalangeal tufts are small, but no overt signs of acroosteolysis are
apparent (Fig. 1b left panel).
Patient 5 was born from Pakistani, reportedly unrelated parents.
Since the age of 3, he was followed due to growth retardation (height
b3rd centile at 5 years of age) and anemia (Hb 8.8 g/dl). Recently, skel-
etal survey showed the presence of osteopetrotic radiological signs
including generalized increase in bone density (Fig. 1b right panel),
cranial sclerosis particularly at the skull base (Fig. 1a bottom), widening
of anterior ribs and long bone metaphysis, Erlenmeyer ﬂask deformity
of distal femurs and suggested "sandwich vertebrae" (Fig. 1c). However,
the loss of the mandible angle and the presence of wormian bones
might have suggested a diagnosis of Pycnodysostosis (Fig. 1a bottom).
He is alive at 5 years in reasonably good conditions.In all patients laboratory ﬁndings regarding the immune compart-
ment were within a normal range, even though no extensive character-
ization was done.
Molecular results
Weperformed exome sequencing in the 2 affected siblings of Family
1 and achieved in both patients a 69× mean coverage over the 62 Mb
targeted exome, with more than 94% of targeted regions covered. The
overall transition to transversion rate (Ti/Tv) was 2.50 in line with
what was expected for exome sequencing. The analysis identiﬁed a
total of 179143 variants which were ﬁltered with dbSNP137 and 1000
Genome Project and according to the pattern of inheritance of the
disease and to the parental consanguinity (Table 1). Among the homo-
zygous variants, we found a mutation in exon 3 of the CTSK gene
(g.2128C N T) which could be considered responsible for the disease
in Patients 1A and 1B (Table 2); of note, the same mutation, leading to
Table 1
Number of variants/genes identiﬁed in patients 1A and 1B through exome sequencing.
Total variants 179143
Shared variants after base quality ﬁltering 126965
Homozygous variants 16082
Non-synonymous/indel/splice site variants 3525
Novel variants (dbSNP137/1000GP queried) 165
Genes with plausible disease association 3
125A. Pangrazio et al. / Bone 59 (2014) 122–126an amino acid substitution at codon 46 (p.Arg46Trp), was already
known to cause Pycnodysostosis [16]. The nucleotide change was con-
ﬁrmed by Sanger sequencing in the homozygous state in the patients
and in the heterozygous state in their parents (Supplementary Fig. 1,
which also shows the mutations found in the other patients).
This ﬁnding prompted us to sequence the CTSK gene in other 25
patients sent us with a clinical diagnosis of autosomal recessive
osteopetrosis (ARO) but in whom we could not identify a molecular
defect in the known ARO genes [3]. Among these patients we identiﬁed
4 individuals bearingmutations in the CTSK gene. In particular, Patient 2
was a compound heterozygote for the nucleotide change above
described and a deletion of 3 nucleotides in exon 4 (g.2343_2345del),
leading to the deletion of a single residue (p.Lys89del). Her father was
heterozygous for the missense mutation, while maternal DNA was not
available as the patient's mother deceased several years earlier.
Patient 3washomozygous for a transversion in exon4 (g.2340A N C)
leading to an amino acid substitution at codon 88 (p.Gln88Pro); this
nucleotide change was conﬁrmed in her parents in the heterozygous
state.
Patient 4 was compound heterozygous for a nucleotide change
in exon 3 (g.2131C N A), causing an amino acid substitution at codon
47 (p.Arg47Ser), and a deletion of 2 nucleotides in exon 6
(g.8746_8747del), causing a frameshift and a premature protein termi-
nation (p.Ser246CysfsX4).
Patient 5 was homozygous for the same nucleotide change found in
patients 1A, 1B and 2 (g.2128C N T); his parents carried thismutation in
the heterozygous state.
Apart from p.Arg46Trp, the other changes are herein described for
the ﬁrst time. The 3 missense mutations (p.Arg46Trp, p.Arg47Ser and
p.Gln88Pro) and the single amino acid deletion (p.Lys89del) are located
in the CTSK proregion, while the frameshift (p.Ser246CysfsX4) affects
the mature enzyme.
As already reported for Arg46, the neighboring Arg47 is highly
conserved among species and is also found in the corresponding posi-
tion in human cathepsins K, S and L [16].
Themissense substitutions (p.Arg46Trp, p.Arg47Ser andp.Gln88Pro)
and the single amino acid deletion (p.Lys89del) were not found inmore
than 100 chromosomes from healthy unrelated individuals from the
same geographical area, and were not present in SNP databases; there-
fore they are unlikely to be neutral polymorphisms. Of note, in silico
analysis using several tools (Mutation Taster, PolyPhen-2, SIFT, Provean)
predicted a damaging effect for all of them.Table 2
Molecular ﬁndings in 6 new CTSK-dependent patients.
Patient Genomic changea Location in DNA




















a Accession number genomic sequence of the CTSK gene: NC_000001.10.
b Accession number of the CTSK cDNA: NM_000396.2; the numbering used starts with nucleIn addition, exome sequencing data in the affected siblings of Family
1 detected a number of known both homozygous and heterozygous
single nucleotide variants (SNV) in a set of genes already associated
with bone defects or bone mineral density (Supplementary Table 1).
In this list, we selected exonic non-synonymous SNVs with a minor
allele frequency below 0.1 in both the Exome Sequencing Project
(ESP6500) and the 1000 Genome Project; this value was chosen based
on the hypothesis that variants less frequent in the general population
might more importantly impact on the disease-causing allele. We spec-
ulated that the presence of one or more speciﬁc SNVs in all the patients
here described could modify the classical pycnodysostotic phenotype.
So, we genotyped the selected variants in all six patients, but we could
not identify a shared genotype or SNV (Supplementary Table 2).
Discussion
To date, themolecular and cellular basis of a considerable number of
genetic disorders is still unknown and this knowledge gap is reﬂected in
not always satisfactory diagnostic and therapeutic strategies. However,
the contribution of new, high-throughput techniques for the sequenc-
ing of the human genome has importantly speeded up the identiﬁcation
of the genes responsible for many diseases. In particular exome
sequencing has come to the fore only few years ago, but has already
widely demonstrated its power in identifying both new disease genes
and new genotype–phenotype associations [17]. Our results further
support the role of exome sequencing in the differential diagnosis of
genetically heterogeneous diseases. The clinical presentation of 6
patients in our cohort was originally described as mild osteopetrosis,
but molecular analysis failed to detect mutations in any of the genes
known to cause this phenotype in humans. Exome sequencing in 2
affected siblings detected a mutation in the CTSK gene already reported
in Pycnodysostosis [16], and mutations in the same gene were subse-
quently found in the remaining 4 affected individuals. Pycnodysostosis
shares with ARO some clinical features, such as a generalized increase
in bone density, frontal bossing, short stature, delayed abnormal tooth
eruption and fragility fractures. Indeed, one of the 2 original descrip-
tions of Pycnodysostosis in 1962 named it an osteopetrosis variant
[18,19]. However, Pycnodysostosis is usually a progressive but relatively
benign condition. It presents in the ﬁrst years of lifewith short stature, a
peculiar facial appearance with bi-temporal narrowing, and clinical and
radiographic signs such as stubby hands and feet with acroosteolysis,
hypoplasia of the maxilla and absence of the mandible angle, which
are considered essentially pathognomonic [20,21]. Evaluation of the
radiographic documentation available from 3 out of 6 patients showed
in 2 of them absence of the obtuse mandible angle on a craniolateral
view, and in all of them absence of obvious acroosteolysis of the
hands, thus suggesting that the radiological evidence was not sufﬁcient
for an unequivocal clinical classiﬁcation.
Variants in other genes involved in bone homeostasis might have
impacted on the radiological presentation of these patients. Proving



























otide +1 for the A of the ATG-translation initiation codon.
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to coding, non-synonymous SNV with low frequency in the general
population, found in genes related to bone phenotypes; however, this
strategy did not identify a genotype common to all the patients, which
could support the idea of an involvement in disease modulation. A
more comprehensive study including also synonymous and non-
coding variants, genotyping of a larger cohort of patients and functional
studiesmight havemore chances to succeed, but in our case it could not
be performed due to the limited sample size.
Overall, our results show that, when the defects commonly referred
to as pathognomonic of a speciﬁc skeletal disease are absent or are not
evaluated correctly, the radiographic signs of increased bone density
can be non-speciﬁc and insufﬁcient to point at a speciﬁc diagnosis, as
occurred in our patients. In this case, the genetic analysis becomes
crucial. Indeed, several investigators who have applied whole exome
sequencing in the clinical diagnostics have remarked that so-called
“atypical” or incomplete cases that do not fulﬁll the textbook diagnostic
criteria seem to be common [23,24]. In other words, atypical patients
must be muchmore frequent than hitherto appreciated. This is a strong
point in favor of a broader and unbiased approach to molecular
diagnostics.
Exploiting new sequencing technologies, a “gene panel” approach
can be implemented in the diagnosis of conditions that share clinical
signs but have a heterogeneous molecular basis (e.g., lysosomal storage
diseaseswith skeletal involvement or osteogenesis imperfecta and bone
fragility disorders, known to be associated with more than 10 different
genes) [1]. Indeed different platforms designed to enrich the target
regions of genes implicated in speciﬁc bone diseases are under develop-
ment as rapid andpowerful diagnostic tools [25]. An alternative strategy
could consist in limiting the analysis of data from whole exome
sequencing to only the genes relevant to the patient phenotype; this
would allow to increase the number of genes under investigation with-
out repeating the test, in case theﬁrst selected subpanel is negative [26].
In conclusion, although a careful examination of the clinical picture
and of high quality X-raysmight correctly have raised the right diagnos-
tic suspicion in some of our cases, thus avoiding the decision to use the
exome approach, we would recommend that CTSK gene be included in
the molecular diagnosis of intermediate forms of human ARO and,
more in general, of high-density bone conditions, even when Sanger
sequencing is used for the mutation screening.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bone.2013.11.014.Disclosure statement
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